First imaging biomarker for trial enrichment qualified by the EMA
January 2012: C-Path receives a positive opinion from the European Medicines Agency (EMA) on the use of magnetic resonance imaging (MRI) as a tool to select patients with early stage cognitive impairment for Alzheimer’s disease clinical trials.
